Foghorn Therapeutics Inc.

Foghorn Therapeutics is a clinical-stage biotechnology company focused on developing a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. This system is responsible for regulating gene expression in our cells, and breakdowns in this system can lead to a wide range of diseases, including cancer. Foghorn's proprietary Gene Traffic Control® platform allows them to study and target the chromatin regulatory system in a comprehensive and integrated way, enabling the identification and validation of new therapeutic targets.

Foghorn's lead product candidate, FHD-286, is currently in clinical development for the treatment of acute myeloid leukemia (AML). The company is also developing a pipeline of other potential therapies, including selective degraders of SMARCA2, CBP, and EP300, as well as transcription factor disruptors. Foghorn Therapeutics is headquartered in Cambridge, Massachusetts, and has a team of scientists and researchers with extensive experience in biotechnology, platform research, discovery, development, and commercialization.

Foghorn Therapeutics offers a generous benefits package that includes an unlimited paid time off policy, allowing employees to take time off whenever they need to relax and recharge. Additionally, they provide 12 weeks of 100% paid parental leave for birthing/primary parent and primary guardian in case of adoption, and 3 weeks of 100% paid parental leave for non-birthing/non-primary parent/guardian. This flexible work environment fosters a healthy work-life balance and promotes employee well-being.

Foghorn Therapeutics offers a comprehensive benefits package to its employees, prioritizing their health and well-being. Full-time employees receive highly competitive medical, dental, and vision coverage options, including PPO and PPO HSA plans. They also have access to FSA and HSA for medical expenses and dependent care. Foghorn provides a 401(k) program with company matching, a corporate wellness program, and an unlimited paid time off policy. In addition, employees enjoy a winter shutdown, 12 weeks of 100% paid parental leave for birthing or primary guardians, and 3 weeks of paid parental leave for non-birthing guardians. The company also provides paid life, LTD, and STD insurance, free parking, subsidized commuter passes, or a monthly stipend for alternative commutes.

Foghorn Therapeutics is a clinical-stage biotechnology company committed to developing a new class of precision medicines that target the chromatin regulatory system. Their mission is to treat serious diseases, including cancer, by correcting abnormal gene expression. Their unique Gene Traffic Control® platform allows them to study and target the chromatin regulatory system at scale, in context, and in an integrated way. They are driven by a deep understanding of this fundamental system and are committed to making a real difference in the lives of people with a wide spectrum of diseases.

Foghorn Therapeutics fosters a collaborative and people-centric culture, where diversity and inclusion are valued, and employees are encouraged to share their ideas and perspectives freely. The company prioritizes a data-driven approach to decision making, fostering an environment where relationships can thrive and innovation flourishes. This culture is reflected in their "People First, Mission Always" mantra, which emphasizes the importance of both individual well-being and a relentless commitment to improving the lives of patients through scientific advancements.

Foghorn Therapeutics is committed to building a diverse and inclusive workplace that values the unique perspectives and experiences of its team members. They believe that a culture of inclusion fosters innovation and creates a more equitable environment for all employees. Foghorn actively promotes diversity through its recruitment practices, employee resource groups, and company-wide initiatives that focus on creating a welcoming and respectful workplace for everyone.